not all positive, page-4

StormBringer, You obviously dont know what you are on about! on a 50/50 split PSD had to fund the trials on the same basis. Under the 20/80 split the funding is responsibility of Alemera. This of the cash requirement that has just been eliminated, not to mention risk. Now if we are looking at bluesky success of the Medidure product lets think what 20% is worth with no funding requirents.

No matter how you slice it its an amazing deal. 25mil in the bank approx 800 mil shares on issue, thats 3c a share cash backing.

But wait there is more:
1. Pfizer Deal
2. Brachasyl
3. Retesert
4. Cash from AION
5. Cash from Psinutria

What more can I say. At 8c this stock is riculously CHEAP!